EMA Authorised: Zavesca (miglustat) — Advanz Pharma Limited

View source ↗

Summary

Authorization granted for Zavesca (miglustat) to Advanz Pharma Limited for Gaucher disease and Niemann-Pick diseases in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease
• Niemann-pick Disease

Drugs mentioned

• Zavesca (Miglustat)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease;Niemann-Pick Diseases. MAH: Advanz Pharma Limited. Decision date: 02/07/2026